Indication: HER2- Locally Advanced Metastatic Breast Cancer
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced Or Metastatic Breast Cancer
Sub-indication: Breast Cancer
Study Type: Drug Study
Principal Investigator: Jeffrey Hargis, M.D.Norton Cancer Institute
Sponsor: Sponsor: F. Hoffmann-LaRoche Ltd.